The Effects of Qinggan-27 Recipe on Nonalcoholic Steatohepatitis Induced by High-fat Diet in Rats

Authors

  • WenJun Department of Traditional Prescriptionology, International School of Mongolian Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia
  • Khaliun Erdenebat Department of Pathology and Forensic Medicine, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia
  • Tserentsoo Byambaa Department of Traditional Prescriptionology, International School of Mongolian Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia
  • Bayarmaa Enkhbat Department of Pathology and Forensic Medicine, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia
  • Enkhtuguldur Myagmar-Ochir Department of epidemiology and biostatistics, School of Public Health, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia
  • Sayamaa Lkhagvadorj Department of Pathology and Forensic Medicine, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia https://orcid.org/0000-0001-6924-8715

DOI:

https://doi.org/10.24079/cajms.2024.03.001

Keywords:

disease model, non-alcoholic fatty liver, Mongolian medicine, PGC-1α, UCP-2

Abstract

 Objective: The Qinggan-27 (QG-27) recipe is a traditional Mongolian medicine believed to improve liver function during Non-alcoholic steatohepatitis (NASH). We developed fatty liver models in rats by intragastric administration of a high-fat diet (HFD) to investigate the effects of the QG-27 recipe on the NASH model through the expression of PGC-1 α and UCP-2. Methods: Wister rats were fed with specially prepared HFD to create a pathological model for 6 weeks. After successful modeling, the patient was treated with QG-27 twice daily with intra­gastric administration of QG-27 at 150 mg/kg, 300 mg/kg, and 600 mg/kg, respectively, for 21 days. Biochemical, histopathological, and immunohistochemical analyses were conducted to evaluate the effect of QG-27 treatment. Results: Levels of AST, ALT, LDL-C, TG, and TC were significantly decreased, and HDL-C was increased in the intermediate dose of the QG-27 group compared to the control group (p<0.05). Immunohistochemical results demonstrated that an intermediate dose of the QG-27 recipe could significantly improve liver function in rats with fat­ty liver by increasing PGC-1α and UCP-2 expression. Conclusion: The intermediate (300 mg/ kg) dose of the QG-27 is a good candidate to be a dietary supplement for reducing fatty liver.

Downloads

Abstract
10
PDF
11

Author Biographies

Bayarmaa Enkhbat, Department of Pathology and Forensic Medicine, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia

Department of Pathology, Mongolia-Japan Hospital, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia

Sayamaa Lkhagvadorj, Department of Pathology and Forensic Medicine, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia

Department of Pathology, Mongolia-Japan Hospital, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia;

References

1. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors, and pre¬vention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11-20. https://doi:10.1038/nrgastro.2017.109

2. Marjot T, Moolla A, Cobbold JF, et al. Nonalcoholic fat¬ty liver disease in adults: current etiology, outcomes, and management concepts. Endocr Rev. 2020;41(1). https:// doi:10.1210/endrev/bnz009

3. Diehl AM, Day C. Cause, pathogenesis, and treatment of non¬alcoholic steatohepatitis. N Engl J Med. 2017;377(21):2063- 2072. https://doi:10.1056/NEJMra1503519

4. The Resolution of the Government of Mongolia is the sec¬ond national program for preventing and controlling diseas¬es caused by wrong lifestyles; 2017

5. Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68(2):280-295. https://doi:10.1016/j.jhep.2017.11.014

6. Spahis S, Delvin E, Borys J, et al. Oxidative stress as a crit¬ical factor in nonalcoholic fatty liver disease pathogene¬sis. Antioxid Redox Signal. 2017;26(10):519-541. https:// doi:10.1089/ars.2016.6776

7. Dey A, Swaminathan K. Hyperglycemia-induced mitochon¬drial alterations in the liver. Life Sci. 2010;87(7-8):197-214. https://doi:10.1016/j.lfs.2010.06.007

8. Price NL, Gomes AP, Ling AJY, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012;15(5):675-690. https://doi:10.1016/j.cmet.2012.04.003

9. Whitaker RM, Corum D, Beeson CC, et al. Mitochondrial biogenesis as a pharmacological target: a new approach to acute and chronic diseases. Annu Rev Pharmacol Toxi¬col. 2016;56:229-249. https://doi:10.1146/annurev-pharm¬tox-010715-103155

10. Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Bio¬phys Acta. 2011;1813(7):1269-1278. https://doi:10.1016/j. bbamcr.2010.09.019

11. Besse-Patin A, Leveille M, Oropeza D, et al. Estrogen signals through peroxisome proliferator-activated receptor-gamma coactivator one alpha to reduce oxidative damage asso¬ciated with diet-induced fatty liver disease. Gastroenter¬ology. 2017;152(1):243-256. https://doi:10.1053/j.gas-tro.2016.09.017

12. Westerbacka J, Kolak M, Kiviluoto T, et al. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/mac¬rophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes. 2007;56(11):2759-2765. https://doi:10.2337/db07-0156

13. Yeh GY, Eisenberg DM, Kaptchuk TJ, et al. A systematic re¬view of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care. 2003;26(4):1277-1294. https:// doi:10.2337/diacare.26.4.1277

14. Xu L, Zhao W, Wang D, et al. Chinese medicine in the bat¬tle against obesity and metabolic diseases. Front Physiol. 2018;9:850. https://doi:10.3389/fphys.2018.00850

15. Cicero AFG, Colletti A, Bellentani S. Nutraceutical approach to non-alcoholic fatty liver disease (NAFLD): the available clinical evidence. Nutrients. 2018;10(9):1153. https:// doi:10.3390/nu10091153

16. Zhong S, Fan Y, Yan Q, et al. The therapeutic effect of sily¬marin in treating nonalcoholic fatty disease: A meta-anal¬ysis (PRISMA) of randomized control trials. Medicine (Baltimore). 2017;96(49):e9061. https://doi:10.1097/ MD.0000000000009061

17. Zhanbala CDF. Secrets of Fanghai, Inner Mongolia People’s Publishing House, Hohhot;2014

18. Lei P, Tian S, Teng C, et al. Sulforaphane improves lipid metab¬olism by enhancing mitochondrial function and biogenesis in vivo and in vitro. Mol Nutr Food Res. 2021;65(11):e2170023. https://doi:10.1002/mnfr.202170023

19. Chen Z, Tian R, She Z, et al. Role of oxidative stress in non¬alcoholic fatty liver disease pathogenesis. Free Radic Biol Med. 2020;152:116-141. https://doi:10.1016/j.freerad-biomed.2020.02.025

20. St-Pierre J, Drori S, Uldry M, et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 tran¬scriptional coactivators. Cell. 2006;127(2):397-408. https:// doi:10.1016/j.cell.2006.09.024

21. Rabinovitch RC, Samborska B, Faubert B, et al. AMPK main¬tains cellular metabolic homeostasis through the regula¬tion of mitochondrial reactive oxygen species. Cell Rep. 2017;21(1):1-9. https://doi:10.1016/j.celrep.2017.09.026

22. Tserendagva D. Malnutrition, poor blood, blood-separa¬tion, satiety relationship of the bloodletting therapy. The¬sis submitted for the degree of Science Doctor in Medical Education. Mongolian National University of Medical Sci¬ences. Mongolian State Academy of Sciences, Ulaanbaatar. 2018;23

23. Xin QI, Hong-Qing LI. Protective effects of Qinggan-27 pills on mouse models of alcoholic liver damage. Chi Trad Patent Med; 2018(12):260-265

24. Avwioro G. Histochemical uses of haematoxylin-a review. J Physics Conf Series. 2011;1:24-3

Downloads

Published

2024-09-30

How to Cite

WenJun, Erdenebat, K., Byambaa, T., Enkhbat, B., Myagmar-Ochir, E., & Lkhagvadorj, S. (2024). The Effects of Qinggan-27 Recipe on Nonalcoholic Steatohepatitis Induced by High-fat Diet in Rats. Central Asian Journal of Medical Sciences, 10(3), 85–94. https://doi.org/10.24079/cajms.2024.03.001

Issue

Section

Articles